Literature DB >> 10510388

Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).

H Winter1, H M Hu, W J Urba, B A Fox.   

Abstract

The adoptive transfer of tumor-specific effector T cells can result in complete regression and cure mice with systemic melanoma, but the mechanisms responsible for regression are not well characterized. Perforin- and Fas ligand (APO-1/CD95 ligand)-mediated cytotoxicity have been proposed as mechanisms for T cell-mediated tumor destruction. To determine the role of perforin and Fas ligand (FasL) in T cell-mediated tumor regression in a murine melanoma model, B16BL6-D5 (D5), we generated D5-specific effector T cells from tumor vaccine-draining lymph nodes of wild type (wt), perforin knock out (PKO), or FasL mutant (gld) mice and treated established D5 metastases in mice with the same genotype. Effector T cells from wt, PKO and gld mice induced complete regression of pulmonary metastases and significantly prolonged survival of the treated animals regardless of their genotype. Complete tumor regression induced by PKO effector T cells was also observed in a sarcoma model (MCA-310). Furthermore, adoptive transfer of PKO and wt effector T cells provided long-term immunity to D5. Therapeutic T cells from wt, PKO, or gld mice exhibit a tumor-specific type 1 cytokine profile; they secrete IFN-gamma, but not IL-4. In these models, T cell-mediated tumor regression and long-term antitumor immunity are perforin and FasL independent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510388

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.

Authors:  Christopher G Twitty; Shawn M Jensen; Hong-Ming Hu; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2011-08-02       Impact factor: 12.531

2.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

Review 3.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

4.  Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells.

Authors:  Dominik Rüttinger; Rui Li; Walter J Urba; Bernard A Fox; Hong-Ming Hu
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

6.  Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

Authors:  Anil Shanker; Alan D Brooks; Kristen M Jacobsen; John W Wine; Robert H Wiltrout; Hideo Yagita; Thomas J Sayers
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

7.  Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor.

Authors:  Frank-Peter Wachs; René C Krieg; Cecilia M P Rodrigues; Helmut Messmann; Frank Kullmann; Ruth Knüchel-Clarke; Jürgen Schölmerich; Gerhard Rogler; Klaus Schlottmann
Journal:  Int J Colorectal Dis       Date:  2004-09-07       Impact factor: 2.571

8.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  DICE: A novel tumor surveillance mechanism-a new therapy for cancer?

Authors:  Marcus E Peter
Journal:  Cell Cycle       Date:  2014-04-01       Impact factor: 4.534

10.  Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Authors:  Mireia Uribe-Herranz; Kyle Bittinger; Stavros Rafail; Sonia Guedan; Stefano Pierini; Ceylan Tanes; Alex Ganetsky; Mark A Morgan; Saar Gill; Janos L Tanyi; Frederic D Bushman; Carl H June; Andrea Facciabene
Journal:  JCI Insight       Date:  2018-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.